Navigation Links
InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
Date:10/16/2008

- Provides Progress Report on InterMune Phase 3 CAPACITY Program -

- Reports 97% patient retention rate in CAPACITY -

BRISBANE, Calif., Oct. 16 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today reported that on October 16, 2008, the Japanese Ministry of Health, Labor and Welfare (MHLW) approved the New Drug Application (J-NDA) submitted by Shionogi & Co. Ltd. to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in Japan. Pirfenidone was developed in Japan for the treatment of IPF by Shionogi, which has rights to pirfenidone in Japan, Taiwan and South Korea.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "We are very encouraged by the Japanese regulatory approval of pirfenidone for IPF, making pirfenidone the first medicine approved for IPF patients in any major market in the world."

InterMune also provided a progress report on its Phase 3 CAPACITY program of pirfenidone in IPF. CAPACITY consists of two multinational, randomized, double-blind, placebo-controlled Phase 3 studies with a total enrollment of 779 IPF patients at 110 centers in the United States, Europe and Australia. The primary endpoint in CAPACITY is change in Forced Vital Capacity (FVC) from baseline to week 72.

InterMune reported that 97% of transplant-free, surviving patients had completed their Week 72 Visit, the study visit at which the primary endpoint is assessed.

The CAPACITY protocol calls for a final patient visit to be completed 30 days after the Week 72 Visit. This means that all patient visits for CAPACITY are expected to be completed around the end of October 2008. Based on this timeline for study completion, InterMune expects t
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... (PRWEB) April 21, 2015 Staying true ... to craft a digital product that makes the world ... with Global Biological Standards Institute (GBSI) to redesign their ... clean, and most importantly, strategy-based. , "Biomedical research is ... - much less to promote it in a narrative ...
(Date:4/21/2015)... , April 21, 2015 ... and development, custom automation, and contract manufacturing, and  ... accessible flow cytometry and cell sorting technology for ... develop a novel flow cytometry platform. ... NanoCellect Biomedical has developed a microchip-based cell sorting ...
(Date:4/21/2015)... , April 21, 2015  Tute Genomics, a leading ... of Josh Forsythe as VP of Marketing. Mr. ... witnessed a significant expansion in its commercial operations over the ... " Josh Forsythe is a tremendous addition ... MD MBA, CEO of Tute Genomics. "Josh,s vast experience commercializing ...
(Date:4/21/2015)... and RESEARCH TRIANGLE PARK, N.C. , ... UTHR ) announced today that it will release ... on Tuesday, April 28, 2015. United Therapeutics ... 2015, at 9:00 a.m. Eastern Time.  The teleconference is ... A rebroadcast of the teleconference will be available for ...
Breaking Biology Technology:Visceral Tells GBSI’s Story Within 30 Seconds of Attention 2Visceral Tells GBSI’s Story Within 30 Seconds of Attention 3NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 2NanoCellect And Invetech Announce Collaboration To Develop Novel Flow Cytometry Platform For Cell Sorting And Analysis 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4
... 18 Danaher Corporation (NYSE: DHR ) announced today ... indirect wholly owned subsidiary, to acquire all of the issued and ... pence per share implying an aggregate price of approximately GBP 50 ... The offer enjoys the recommendation of the Board of Genetix who ...
... , Toronto Stock Exchange Symbol: ... (TSX: MS) today provided the following update on corporate developments: ... -----------------, , The Company has completed its substantive review of ... drug candidate for the treatment of multiple sclerosis (MS). BioMS ...
... , , , , ... stem cell based,technology of Cellonis Biotechnologies, Beijing, a Chinese research/medical,team ... 36 year old Norwegian,patient in a hospital in Beijing. The ... stem cells as well as cancer daughter,cells. The amazing outcome ...
Cached Biology Technology:Danaher Offers to Acquire Genetix Group plc for GBP 50 million pounds Sterling (USD $82 million) 2BioMS Medical provides corporate update 2BioMS Medical provides corporate update 3For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 2For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 3For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 4
(Date:4/20/2015)... DUBAI , April 20, 2015 ... soars   Glenbeigh Records Management (GRM), ... contract with Dubai Islamic Bank. Having built up an impressive ... is now a leading player within the records management sector ... company expects to double is GCC staffbase and employ a ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... office on the Texas A&M University campus, Dr. Marty Dickman,s ... pursuit of scientific excellence that,s what,s fun," Dickman said. ... is to understand what the problems are, how things work ... Dickman paused briefly and with gratitude recently to reflect on ...
... Ten researchers at the University of California, Riverside have ... of Science ( AAAS ). Including this year,s fellows, the ... with AAAS Fellow distinction is 190. Election as a ... peers. This year AAAS gave this honor to 503 of ...
... Iowa State University two of them are also affiliated ... been named fellows of the American Association for the Advancement ... their award citations are: Srinivas ... of Computer Engineering, "For distinguished contributions to high performance computational ...
Cached Biology News:Marty Dickman named AAAS Fellow 210 UC Riverside researchers recognized by the American Association for the Advancement of Science 210 UC Riverside researchers recognized by the American Association for the Advancement of Science 3AAAS honors Iowa State, Ames Lab researchers for distinguished science 2
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
...
Antibody Diluent for IHC 125 ml...
Biology Products: